|
| Perspective From Industry Leaders |
|
|
| Don't Compromise The Pharma Innovation System; Says Outgoing IFPMA Head Thomas Cueni | Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company |
|
Thomas Cueni is stepping down after seven years at the helm of the International Federation of... |
Boehringer Ingelheim has become Germany’s biggest company in the sector by pharma revenues, overtaking its... |
| Licensing & Collaboration Agreements |
|
|
| Healios Acquires Bankrupt Athersys, Expands Cell Therapy R&D Programs | Deal Watch: Gilead Acquires Xilio’s IL-12 Activating Candidate |
|
Regenerative medicine-focused Japanese biotech Healios K.K. has acquired its long-time US collaborator Athersys... |
Gilead Sciences, Inc. obtained exclusive rights on 28 March to develop and sell Xilio Therapeutics, Inc.’s Phase I... |
| Next Gen R&D |
|
|
| AstraZeneca’s Next-Gen PARP Inhibitor Hints At Better Safety And Efficacy In Breast Cancer | Rare Cancer Development Consortium Moving Toward Target Selection |
|
AstraZeneca may just have found a worthy successor to its blockbuster PARP inhibitor drug Lynparza... |
National Cancer Institute officials will select the first targets for the US Food and Drug Administration-initiated... |
| Clinical Trials |
|
|
| Roivant May Take On AbbVie In Uveitis With Strong Phase II Efficacy | Amylyx’s Relyvrio Withdrawal May Trigger More Public Pledges Based On Confirmatory Trial Data |
|
Roivant Sciences Ltd. said it is poised to take on AbbVie Inc.’s Humira in non-infectious uveitis, a leading cause... |
Some may question whether the US Food and Drug Administration will be less willing to exercise regulatory flexibility... |
|
|
|
Citeline Contact Poornachandra Tejasvi .K, 
|
IPA Contact Name: Hari Pranav K |